Most Popular

Maxim Raises Keryx Price Target To $26 Following Ferric Citrate Pricing

In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) and slightly raised his …

H.C. Wainwright Reiterates Buy On Ariad Following Clinical Data On AP26113

In a research report released today, H.C.

Piper Jaffray Reiterates Buy On Inovio As The Stock Is Rising Above The Noise with Ebola

In a research report released today, Piper Jaffray analyst Charles Duncan reiterated a Overweight rating on Inovio Pharmaceuticals (NASDAQ:INO) with a $29 price target, as the company recently …

Is It A Good Time To Accumulate InvenSense? Roth Capital Says Yes

In a research report published today, Roth Capital analyst Krishna Shankar assigned a Buy rating on InvenSense Inc (NYSE:INVN) with a $28 price target, which represents …

Oppenheimer Reiterates Outperform On Opko Health On The Heels Of Rayaldee Positive Top-Line Data

In a research report issued today, Oppenheimer analyst Rohit Vanjani reiterated an Outperform rating on Opko Health (NYSE:OPK) with a $12 price target, following yesterday’s news …

Maxim Group Maintains Buy On Gilead On The Heels Of New Drug Application In Japan

In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Gilead Sciences (NASDAQ:GILD) with a $127 price …

H.C. Wainwright Comments On Neuralstem Following Presentation At The Annual Symposium On ALS

In a research report issued today, H.C.

Maxim Group Reiterates Buy On Inovio Pharmaceuticals Following Initiation Plans For Phase 1 Study

In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Inovio Pharmaceuticals (NYSE:INO) with a $18 price target, as the …

H.C. Wainwright Reiterates Buy On Oxigene Following Initiation Of Phase 2 Study

In a research report issued today, H.C.

Roth Capital Comments On Sarepta As Pivotal Study Dosing Delayed

In a research report issued today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $34 price target, following …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts